Interim Management Statement 1 January – 31 March 2019

Key figures

  • -0%

    LC SALES

  • -0%

    EURO SALES

  • 0%

    OPERATING MARGIN

€m Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19
Net Sales LTM 1,209.6 1,218.1 1,233.8 1,249.4 1,283.7 1,321.8 1,338.1 1,363.1 1,357.1 1,331.4 1,328.7 1,318.9 1,257.2
Op. Margin % LTM 8.6% 9.0% 9.4% 9.5% 10.0% 10.4% 10.8% 11.7% 11.8% 11.9% 11.7% 11.3% 12.0%

Markets

  • Latin America
    +0%

    Local currency sales

  • Europe & Africa
    +0%

    Local currency sales

  • CIS
    0%

    Local currency sales

  • Asia & Turkey
    -0%

    Local currency sales

Sales

Sales (%) Latin America Europe & Africa CIS Asia & Turkey
2019-Q1 12 27 26 35
2018-Q1 10 24 26 40

Registered actives

Registered actives (%) Latin America Europe & Africa CIS Asia & Turkey
2019-Q1 10 26 32 32
2018-Q1 9 25 28 38

Operating profit

Operating profit (%) Latin America Europe & Africa CIS Asia & Turkey
2019-Q1 7 28.0 19 46
2018-Q1 9 19 18 54

Operational highlights

Ecollagen Wrinkle Power

The main initiative within Skin Care during the quarter were the introduction of the new Ecollagen Wrinkle Power, clinically proven to reduce wrinkles by combining the patented Tri-Peptide and plant stem cells anti-wrinkle technology with low molecular hyaluronic acid.